Prospects for Aldeyra's dry eye disease candidate reproxalap were hit last month after the drug failed to hit its primary objective in a phase 3 trial, but the company isn't giving up and h
Biogen has scaled back its ambitions for Denali-partnered Parkinson’s disease candidate BIIB122, abandoning a complex and likely costly phase 3 trial that isn’t due to com
Health systems globally have reached a critical inflexion point, where ageing populations and tightening budgets mean we can no longer continue to purely treat late-stage symptomatic diseas
